These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 15949121)

  • 1. High participation rates are not necessary for cost-effective colorectal cancer screening.
    Howard K; Salkeld G; Irwig L; Adelstein BA
    J Med Screen; 2005; 12(2):96-102. PubMed ID: 15949121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of screening for colorectal cancer in France using a guaiac test versus an immunochemical test.
    Lejeune C; Dancourt V; Arveux P; Bonithon-Kopp C; Faivre J
    Int J Technol Assess Health Care; 2010 Jan; 26(1):40-7. PubMed ID: 20059779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis on screening for colorectal neoplasm and management of colorectal cancer in Asia.
    Tsoi KK; Ng SS; Leung MC; Sung JJ
    Aliment Pharmacol Ther; 2008 Aug; 28(3):353-63. PubMed ID: 18638075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of colorectal cancer screening in renal transplant recipients.
    Wong G; Howard K; Craig JC; Chapman JR
    Transplantation; 2008 Feb; 85(4):532-41. PubMed ID: 18347531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of the optimal threshold of an automated immunochemical test for colorectal cancer screening: performances of immunochemical colorectal cancer screening.
    Berchi C; Guittet L; Bouvier V; Launoy G
    Int J Technol Assess Health Care; 2010 Jan; 26(1):48-53. PubMed ID: 20059780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Limitations of the faecal occult blood test in screening for colorectal cancer.
    Delcò F; Sonnenberg A
    Ital J Gastroenterol Hepatol; 1999 Mar; 31(2):119-26. PubMed ID: 10363196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Colorectal cancer screening with faecal occult blood test within a multiple disease screening programme: an experience from Keelung, Taiwan.
    Yang KC; Liao CS; Chiu YH; Yen AM; Chen TH
    J Med Screen; 2006; 13 Suppl 1():S8-13. PubMed ID: 17227635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential impact of population-based colorectal cancer screening in Canada.
    Flanagan WM; Le Petit C; Berthelot JM; White KJ; Coombs BA; Jones-McLean E
    Chronic Dis Can; 2003; 24(4):81-8. PubMed ID: 14733756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening of colorectal cancer.
    Winawer SJ
    Surg Oncol Clin N Am; 2005 Oct; 14(4):699-722. PubMed ID: 16226687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis for determining optimal cut-off of immunochemical faecal occult blood test for population-based colorectal cancer screening (KCIS 16).
    Chen LS; Liao CS; Chang SH; Lai HC; Chen TH
    J Med Screen; 2007; 14(4):191-9. PubMed ID: 18078564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of two strategies for mass screening for colorectal cancer in France.
    Berchi C; Bouvier V; Réaud JM; Launoy G
    Health Econ; 2004 Mar; 13(3):227-38. PubMed ID: 14981648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and economic impact of screening for colorectal cancer by mass fecal occult blood testing.
    Helm JF; Russo MW; Biddle AK; Simpson KN; Ransohoff DF; Sandler RS
    Am J Gastroenterol; 2000 Nov; 95(11):3250-8. PubMed ID: 11095350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cost-effectiveness evaluation of predictive molecular diagnostics using the example of hereditary non-polyposis colorectal cancer (HNPCC)].
    Hagen A; Hessabi HK; Gorenoi V; Schönermark MP
    Gesundheitswesen; 2008 Jan; 70(1):18-27. PubMed ID: 18273760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes and cost evaluation of the first two rounds of a colorectal cancer screening program based on immunochemical fecal occult blood test in northern Italy.
    Parente F; Boemo C; Ardizzoia A; Costa M; Carzaniga P; Ilardo A; Moretti R; Cremaschini M; Parente EM; Pirola ME
    Endoscopy; 2013; 45(1):27-34. PubMed ID: 23254404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Screening of high-risk group with colorectal cancer].
    Xu AG; Yu ZJ; Zhong XH; Gan AH; Liu JH; Luo QY
    Zhonghua Yi Xue Za Zhi; 2010 Jan; 90(2):116-8. PubMed ID: 20356496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of capsule endoscopy in screening for colorectal cancer.
    Hassan C; Zullo A; Winn S; Morini S
    Endoscopy; 2008 May; 40(5):414-21. PubMed ID: 18302080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A literature review of assumptions on test characteristics and adherence in economic evaluations of colonoscopy and CT-colonography screening.
    van Gils P; van den Berg M; van Kranen H; de Wit AG
    Eur J Cancer; 2009 Jun; 45(9):1554-9. PubMed ID: 19261464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Colorectal cancer screening: advice from the Health Council of the Netherlands].
    van Veen W; Mali WP
    Ned Tijdschr Geneeskd; 2009; 153():A1441. PubMed ID: 20003552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost evaluation in a colorectal cancer screening programme by faecal occult blood test in the District of Florence.
    Grazzini G; Ciatto S; Cislaghi C; Castiglione G; Falcone M; Mantellini P; Zappa M;
    J Med Screen; 2008; 15(4):175-81. PubMed ID: 19106257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health benefits and costs of screening for colorectal cancer in people on dialysis or who have received a kidney transplant.
    Wong G; Li MW; Howard K; Hua DK; Chapman JR; Bourke M; Turner R; Tong A; Craig JC
    Nephrol Dial Transplant; 2013 Apr; 28(4):917-26. PubMed ID: 23182812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.